1. Home
  2. PRTC vs RMNI Comparison

PRTC vs RMNI Comparison

Compare PRTC & RMNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTC
  • RMNI
  • Stock Information
  • Founded
  • PRTC 2015
  • RMNI 2005
  • Country
  • PRTC United States
  • RMNI United States
  • Employees
  • PRTC N/A
  • RMNI N/A
  • Industry
  • PRTC Biotechnology: Pharmaceutical Preparations
  • RMNI Business Services
  • Sector
  • PRTC Health Care
  • RMNI Consumer Discretionary
  • Exchange
  • PRTC Nasdaq
  • RMNI Nasdaq
  • Market Cap
  • PRTC 439.8M
  • RMNI 368.8M
  • IPO Year
  • PRTC N/A
  • RMNI N/A
  • Fundamental
  • Price
  • PRTC $17.90
  • RMNI $3.11
  • Analyst Decision
  • PRTC Buy
  • RMNI Buy
  • Analyst Count
  • PRTC 1
  • RMNI 2
  • Target Price
  • PRTC $45.00
  • RMNI $6.00
  • AVG Volume (30 Days)
  • PRTC 2.0K
  • RMNI 303.4K
  • Earning Date
  • PRTC 04-30-2025
  • RMNI 07-30-2025
  • Dividend Yield
  • PRTC N/A
  • RMNI N/A
  • EPS Growth
  • PRTC N/A
  • RMNI N/A
  • EPS
  • PRTC 0.21
  • RMNI N/A
  • Revenue
  • PRTC $4,828,000.00
  • RMNI $426,212,000.00
  • Revenue This Year
  • PRTC $35.98
  • RMNI $1.38
  • Revenue Next Year
  • PRTC $115.38
  • RMNI $3.97
  • P/E Ratio
  • PRTC $7.81
  • RMNI N/A
  • Revenue Growth
  • PRTC 44.98
  • RMNI N/A
  • 52 Week Low
  • PRTC $13.30
  • RMNI $1.53
  • 52 Week High
  • PRTC $28.39
  • RMNI $4.15
  • Technical
  • Relative Strength Index (RSI)
  • PRTC 46.07
  • RMNI 43.46
  • Support Level
  • PRTC $19.00
  • RMNI $3.27
  • Resistance Level
  • PRTC $19.80
  • RMNI $3.49
  • Average True Range (ATR)
  • PRTC 0.33
  • RMNI 0.20
  • MACD
  • PRTC -0.12
  • RMNI -0.00
  • Stochastic Oscillator
  • PRTC 16.30
  • RMNI 35.07

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

About RMNI Rimini Street Inc. (DE)

Rimini Street Inc and its subsidiaries are providers of end-to-end enterprise software support, products, and services. The Company offers a comprehensive family of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, database, and technology software platforms. The Company derives revenues from clients by providing subscription support services for enterprise resource planning, customer relationship management, product lifecycle management database, and technology software systems. Geographically, the company generates the majority of its revenue from the United States of America and the International market.

Share on Social Networks: